Alliqua's listing on NASDAQ this week will increase the wound care provider's visibility in the market, and ultimately increase its shareholder base, says the company's CEO David Johnson. Shares of the micro-cap biotech have risen 25% so far in 2014 after the company transformed itself in 2013 with a reverse stock split, new management and a major investment from biotech giant Celgene to further its Biovance product line.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

These 5 Stocks Are Primed for Breakouts

6 Stocks Under $10 Making Big Moves Higher

5 Stocks Under $10 Set to Soar

6 Stocks Under $10 Making Big Moves Higher

5 Breakout Stocks Under $10 Set to Soar